Roy M. John
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roy M. John has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Qi Zheng
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
2 shared publicationsUsha B. Tedrow
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
2 shared publicationsWilliam G. Stevenson
Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
2 shared publicationsAmmar M. Killu
Mayo Clinic, Rochester, MN, USA
1 shared publicationBruce A. Koplan
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
1 shared publicationEun-Jeong Kim
Both authors contributed equally to this work
1 shared publication
Latest Publications
- 1 January 2019
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 5 (1) , 104-112
Atrioventricular Block During Catheter Ablation for Ventricular Arrhythmias
- 1 January 2019
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 5 (1) , 104-112
Atrioventricular Block During Catheter Ablation for Ventricular Arrhythmias
- 24 March 2018
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 52 (2) , 163-169
Endomyocardial biopsy at the time of ablation or device implantation
Cardiomyopathies frequently lead to conduction system disease and/or arrhythmias necessitating device therapy, catheter ablation, or both. Endomyocardial biopsy (EMB) is avoided with recent right ventricle (RV) lead implants and optimal timing is uncertain. We determined outcomes of EMB at the time of ablation or device implantation procedures.
- 24 March 2018
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 52 (2) , 163-169
Endomyocardial biopsy at the time of ablation or device implantation
Cardiomyopathies frequently lead to conduction system disease and/or arrhythmias necessitating device therapy, catheter ablation, or both. Endomyocardial biopsy (EMB) is avoided with recent right ventricle (RV) lead implants and optimal timing is uncertain. We determined outcomes of EMB at the time of ablation or device implantation procedures.
- Open Access
- 26 February 2018
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 9 (3) , 3051-3057
Arrhythmias in Cardiac Amyloidosis
Innovations in Cardiac Rhythm Management
- 26 February 2018
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 9 (3) , 3051-3057
Open AccessArrhythmias in Cardiac Amyloidosis
Innovations in Cardiac Rhythm Management
- 1 January 2018
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 7 (1) , 8-10
Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology
Non-invasive ablation of cardiac tissue to control ventricular tachycardia (VT) is a novel therapeutic consideration in the management of ventricular arrhythmias associated with structural heart disease. The technique involves the use of stereotactic radiotherapy delivered to VT substrates. Although invasive mapping can be used to identify the target, the use of non-invasive ECG and imaging techniques combined with multi-electrode body-surface ECG recordings offers the potential of a completely non-invasive approach. Early case series have demonstrated a consistent decrease in VT burden and sufficient early safety to allow more detailed multicenter studies. Such studies are currently in progress to further evaluate this promising technology.
- 1 January 2018
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 7 (1) , 8-10
Non-invasive Cardiac Radiation for Ablation of Ventricular Tachycardia: a New Therapeutic Paradigm in Electrophysiology
Non-invasive ablation of cardiac tissue to control ventricular tachycardia (VT) is a novel therapeutic consideration in the management of ventricular arrhythmias associated with structural heart disease. The technique involves the use of stereotactic radiotherapy delivered to VT substrates. Although invasive mapping can be used to identify the target, the use of non-invasive ECG and imaging techniques combined with multi-electrode body-surface ECG recordings offers the potential of a completely non-invasive approach. Early case series have demonstrated a consistent decrease in VT burden and sufficient early safety to allow more detailed multicenter studies. Such studies are currently in progress to further evaluate this promising technology.